TY - JOUR T1 - Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of <em>R</em>-Enantiomer JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1309 LP - 1318 VL - 27 IS - 11 AU - Partha Roy AU - Olga Tretyakov AU - Joel Wright AU - David J. Waxman Y1 - 1999/11/01 UR - http://dmd.aspetjournals.org/content/27/11/1309.abstract N2 - The anticancer prodrug ifosfamide (IFA) contains a chiral phosphorous atom and is administered clinically as a racemic mixture ofR and S enantiomers. Animal model studies and clinical data indicate enantioselective differences in cytochrome P-450 (CYP) metabolism, pharmacokinetics, and therapeutic efficacy between the two enantiomers; however, the metabolism of individual IFA enantiomers has not been fully characterized. The role of CYP enzymes in the stereoselective metabolism of R-IFA andS-IFA was investigated by monitoring the formation of both 4-hydroxy (activated) and N-dechloroethyl (DCl) (inactive, neurotoxic) metabolites. In the 4-hydroxylation reaction, cDNA-expressed CYPs 3A4 and 3A5 preferentially metabolizedR-IFA, whereas CYP2B6 was more active towardS-IFA. Enantioselective IFA 4-hydroxylation (R &gt; S) was observed with six of eight human liver samples. In the N-dechloroethylation reaction, CYPs 3A4 and 2B6 both catalyzed a significantly higher intrinsic metabolic clearance (Vmax/Km) ofS-IFA compared with R-IFA. Striking P-450 form specificity in the formation of individual DCl metabolites was evident. CYPs 3A4 and 3A5 preferentially produced (R)N2-DCl-IFA and (R)N3-DCl-IFA (derived from R-IFA and S-IFA, respectively), whereas CYP2B6 correspondingly formed (S)N3-DCl-IFA and (S)N2-DCl-IFA. In human liver microsomes, the CYP3A-specific inhibitor troleandomycin suppressed (R)N2- and (R)N3-DCl-IFA formation by ≥80%, whereas (S)N2- and (S)N3-DCl-IFA formation were selectively inhibited (≥85%) by a CYP2B6-specific monoclonal antibody. The overall extent of IFAN-dechloroethylation varied with the CYP3A4 and CYP2B6 content of each liver, but was significantly lower forR-IFA (32 ± 13%) than for S-IFA (62 ± 17%, n = 8; p &lt; .001) in all livers examined. R-IFA thus has more favorable liver metabolic properties than S-IFA with respect to less extensive N-dechloroethylation and more rapid 4-hydroxylation, indicating that R-IFA may have a distinct clinical advantage over racemic IFA. The American Society for Pharmacology and Experimental Therapeutics ER -